December 15, 2014 | The Israeli biomedical company BioLight Lifesciences reportedly plans to launch its cancer diagnosis products in India within the next couple of months. “We will be happier to shift our focus from the US, to sell our products to India designated in particular to cervical cancer as we see a huge potential in the Indian market. This is mainly because of the increase in the number of deaths of many women in India due to cervical cancer than in the US,” says Suzana Nahum Zilberberg, CEO of BioLight. India has seen a spike in recent years in cervical cancer among women, becoming the largest cancer killer among women. BioLight is a public company traded on the Tel Aviv Stock Exchange.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024
TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024
Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024
BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments